Abstract

Galloyl catechins, in particular (-)-epicatechin gallate (ECg), have the capacity to abrogate β-lactam resistance in methicillin-resistant strains of Staphylococcus aureus (MRSA); they also prevent biofilm formation, reduce the secretion of a large proportion of the exoproteome and induce profound changes to cell morphology. Current evidence suggests that these reversible phenotypic traits result from their intercalation into the bacterial cytoplasmic membrane. We have endeavoured to potentiate the capacity of ECg to modify the MRSA phenotype by stepwise removal of hydroxyl groups from the B-ring pharmacophore and the A:C fused ring system of the naturally occurring molecule. ECg binds rapidly to the membrane, inducing up-regulation of genes responsible for protection against cell wall stress and maintenance of membrane integrity and function. Studies with artificial membranes modelled on the lipid composition of the staphylococcal bilayer indicated that ECg adopts a position deep within the lipid palisade, eliciting major alterations in the thermotropic behaviour of the bilayer. The non-galloylated homolog (-)-epicatechin enhanced ECg-mediated effects by facilitating entry of ECg molecules into the membrane. ECg analogs with unnatural B-ring hydroxylation patterns induced higher levels of gene expression and more profound changes to MRSA membrane fluidity than ECg but adopted a more superficial location within the bilayer. ECg possessed a high affinity for the positively charged staphylococcal membrane and induced changes to the biophysical properties of the bilayer that are likely to account for its capacity to disperse the cell wall biosynthetic machinery responsible for β-lactam resistance. The ability to enhance these properties by chemical modification of ECg raises the possibility that more potent analogs could be developed for clinical evaluation.

Highlights

  • There is an on-going need to develop new agents and provide new strategies for the treatment of hospital- and communityacquired infections caused by Staphylococcus aureus

  • epicatechin gallate (ECg) and analogs 1 and 2 possessed very weak intrinsic anti-staphylococcal activity, with Minimum inhibitory concentration (MIC) values of 128 mg/ml; in oxacillin resistance reduction assays, 1 and 2 at a concentration of 12.5 mg/ml were indistinguishable from ECg, modulating susceptibility from 512 to,1 mg/ml

  • We previously established that exposure of logarithmic phase methicillin-resistant S. aureus (MRSA) to ECg for the relatively long period of 4 h induced a substantial number of genes associated with the cell wall stress stimulon [26], a defensive response normally associated with bactericidal cell wall inhibitors [29]

Read more

Summary

Introduction

There is an on-going need to develop new agents and provide new strategies for the treatment of hospital- and communityacquired infections caused by Staphylococcus aureus. This opportunistic pathogen has proven to be adept at acquiring genes encoding resistance mechanisms against front-line antibiotics and, in the absence of appropriate preventative measures, multi-drugresistant forms such as methicillin-resistant S. aureus (MRSA) clones are able to disseminate at sometimes alarming rates amongst patients in healthcare facilities [1,2]. Some have the capacity to interfere with antibiotic resistance mechanisms, converting antibiotic resistant Gram-positive bacteria to a state of phenotypic susceptibility [8,10], and raising the possibility that druggable versions of these molecules could be used therapeutically alongside conventional antibiotics whose utility has been compromised by the dissemination of resistance genes. Use of the highly successful combination of the b-lactamase inhibitor clavulanic acid and the b-lactam agent amoxicillin, marketed as Augmentin, is guided by such principles [11]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.